Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
about
Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSALinezolid versus vancomycin for skin and soft tissue infectionsLinezolid versus vancomycin for skin and soft tissue infectionsCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciNew developments in the management of severe skin and deep skin structure infections - focus on tedizolidPrevention of vancomycin induced nephrotoxicity: a review of preclinical data.Effects of meteorological factors on scrub typhus in a temperate region of China.Linezolid versus vancomycin for skin and soft tissue infections.Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of AmericaClinical management of Staphylococcus aureus bacteremia: a review.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Safety and efficacy of commonly used antimicrobial agents in the treatment of enterococcal infections: a review.Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort studyA propensity score analysis shows that empirical treatment with linezolid does not increase the thirty-day mortality rate in patients with Gram-negative bacteremia.The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infectionsCurrent strategies for the prevention and management of central line-associated bloodstream infections.Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.Predictors of mortality in Staphylococcus aureus BacteremiaClinical update on linezolid in the treatment of Gram-positive bacterial infections.Effect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia.Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis.Effectiveness of sequential intravenous-to-oral antibiotic switch therapy in hospitalized patients with gram-positive infection: the SEQUENCE cohort study.Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unitNewer developments in the treatment of Gram-positive infections.Emerging drugs in sepsis.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy.Prevention and management of central line-associated bloodstream infections in hospital practice.Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.Emerging drugs on methicillin-resistant Staphylococcus aureus.The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection.Linezolid, vancomycin and daptomycin modulate cytokine production, Toll-like receptors and phagocytosis in a human in vitro model of sepsis.Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model.Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors.Acquisition of resistant microorganisms and infections in HIV-infected patients admitted to the ICU.Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design
P2860
Q22305769-EB7706A4-57AA-4950-BB27-093E398DDD08Q24186563-AA4B8D04-4E34-496F-AFCC-522A984DA4A4Q24201228-AF643174-A2DC-4BE0-9489-89748AB3C2CEQ26853465-7F8F4B7F-E856-492E-8018-941BFFD7AEA5Q28083116-CF7F5BD0-ADF0-4946-997A-177B165CAA7EQ30569251-66C45D6F-354E-484F-A0E9-0D6DB71ACAA8Q30815064-051275F3-760C-4FE5-B661-4DE2DA99FA87Q33418740-E37A2280-1F1E-4F37-9F9D-E624343B7AEEQ33617737-1F724E6D-FA79-410A-A8E7-95E6417CF1EAQ33688646-77BB9CC9-ADA3-4700-82A6-CCD6E52B998BQ34441035-7C8E8435-B9EC-41A2-8383-C7B957737308Q34478074-13E6AC4C-B0E3-4DDB-872F-F1C9B70B3C6AQ34503844-02D1D677-94CD-40E1-8221-729C222AFB66Q34583169-0D1EA9F9-B047-44AE-AC44-F566A2404566Q34597369-BA34DD72-25F5-49D7-BFDE-75B03B3479ABQ34618696-E642F11A-9D57-4371-BC89-11E99A0C2F4AQ35026591-F62086DD-E41E-4DD9-A38A-4027635E1A88Q35033597-CA02EA84-6EA5-45F0-9C1B-37D3EBDABD1EQ35940556-D279C20B-BF62-4CEA-9435-618725030C23Q36083208-CA9CD602-0EB1-4BF7-A9D0-EEEFE04B7412Q36172366-ED910034-EEEF-4541-A497-425B1BAF1120Q36206165-178809EE-437F-428C-A15B-B0DC9BC13C61Q37099283-5234292D-CCA3-43AD-9817-DCA7F89672B3Q37443022-113427AD-4333-4AB6-AE5E-EA76DC673ADEQ37636151-E52AAB38-2B5B-4903-8EBC-4FDD17B2FD8CQ37670186-66AFA423-2CB6-426F-AB03-66EE25E10271Q37800939-BEB75E8E-5DD9-478E-99AB-65E6E3DDBC48Q37819539-A246805B-2676-4F5C-BC63-799134708E09Q37992486-4CD1DA2A-3580-466E-9D18-D8A852204FC1Q37992997-79244B05-7F66-492E-8C36-F442611AF280Q38070154-A7475EF5-1067-4698-8E6D-F97B358877C4Q38121142-43C1978C-88AD-4C48-B121-F58789D32CE5Q38132301-F429195E-62F0-4511-AB94-89CD152B943FQ38843037-F1BABE3F-E869-4AC4-89B5-9995C13E911CQ38904168-F53C97B0-472E-4EBA-83C7-57D6A0A93FDCQ39061989-93B2DF1A-D574-455B-B167-4CB3DA58FD5FQ41831306-EF5EB345-182D-4009-BD1A-5CC28166F668Q42220619-B5E25DE0-2335-484C-B41B-95F7BC8489D8Q42243279-DA2D96F3-4468-48A3-841F-E8283B5B88AFQ42544277-810FF561-69CF-4B39-B802-92354F8D99B6
P2860
Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Complicated skin and skin-stru ...... linezolid in a phase 3 study.
@ast
Complicated skin and skin-stru ...... linezolid in a phase 3 study.
@en
Complicated skin and skin-stru ...... linezolid in a phase 3 study.
@nl
type
label
Complicated skin and skin-stru ...... linezolid in a phase 3 study.
@ast
Complicated skin and skin-stru ...... linezolid in a phase 3 study.
@en
Complicated skin and skin-stru ...... linezolid in a phase 3 study.
@nl
prefLabel
Complicated skin and skin-stru ...... linezolid in a phase 3 study.
@ast
Complicated skin and skin-stru ...... linezolid in a phase 3 study.
@en
Complicated skin and skin-stru ...... linezolid in a phase 3 study.
@nl
P2093
P2860
P356
P1476
Complicated skin and skin-stru ...... linezolid in a phase 3 study.
@en
P2093
Bernhard R Ruf
Charles Knirsch
Daniel L Herr
Kenneth J Tack
M Marian Ijzerman
Mark J Kunkel
Rodney V Croos-Dabrera
P2860
P304
P356
10.1086/595686
P407
P577
2009-01-01T00:00:00Z